Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Factor Xa inhibitors prepared and tested by Aventis researchers

June 17, 2003

Dosing under way in phase II catheter occlusion trial of alfimeprase

June 10, 2003

New factor Xa inhibitors, their preparation and use claimed by Kissei scientists

June 10, 2003

rFXIII enters third clinical study, gains orphan drug status

June 6, 2003

Amidine-based factor VIIa inhibitors in early development at Eisai

June 6, 2003

New factor Xa and/or factor VIIa inhibitors under study at Merck KGaA

June 3, 2003

Microbially produced antiplatelet agent identified by Japanese group

June 2, 2003

NM-702 enters late phase II trial for chronic arterial occlusion

May 30, 2003

Japanese sNDA submitted for Cleactor for acute pulmonary embolism

May 28, 2003

Mitsubishi files for European approval of argatroban, establishes German subsidiary

May 28, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.